Lurbinectedin plus pembrolizumab demonstrated “promising efficacy” in patients with relapsed small cell lung cancer (SCLC), according to results from the phase 1/2 LUPER study. Antonio Calles, MD, Hospital General Universitario Gregorio Marañón, and colleagues conducted the study and published their findings in the Journal of Thoracic Oncology. ...
Small Cell Lung Cancer
Advertisement
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The recommendation is based on results from the phase 3 ADRIATIC trial.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
The TROPiCS-03 trial, a multicohort, open-label basket study, is assessing the antibody-drug conjugate in solid tumors.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
Lauren Averett Byers, MD, will be honored with the award during the TAMEST Annual Conference in February.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial.
For patients with Schlafen 11-positive ES-SCLC, atezolizumab plus talazoparib showed an PFS improvement after chemotherapy.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.